Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

Core Insights - Nxera Pharma has received a milestone payment of US$1.8 million from Centessa Pharmaceuticals due to the achievement of an early development milestone for the investigational drug ORX489, which is being developed for neuropsychiatric disorders [1] - The milestone payment will be recognized as revenue in the first quarter of 2026 [1] Company Overview - Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines to address unmet medical needs in Japan and globally [3] - The company operates a new-generation commercial business in Japan, with a pipeline of innovative medicines and several launched products targeting a high-value market in the broader APAC region [3] - Nxera Pharma utilizes its proprietary NxWave™ GPCR structure-based drug discovery platform to advance its extensive pipeline, both internally and through partnerships with leading pharmaceutical and biotech companies [3] - The company has key operational locations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under the ticker 4565 [3]